Morris B J, Millan M J, Herz A
Department of Neuropharmacology, Max-Planck-Institut für Psychiatrie, Planegg-Martinsried, Federal Republic of Germany.
J Pharmacol Exp Ther. 1988 Nov;247(2):729-36.
The neurochemical basis for the supersensitivity to mu or kappa opiate agonists observed after chronic naloxone infusion (reported in the preceding paper) has been investigated using the technique of quantitative in vitro autoradiography. The binding of [3H]-D-Ala2MePhe4Glyol enkephalin (3H-DAGO) to mu opioid sites was increased in many brain regions after chronic administration (7 days) of a low dose of naloxone (0.5 mg/kg/hr). The greatest increases were seen in the hippocampal strata moleculare and lucidum. The binding of [3H]-D-Ala2-D-Leu5 enkephalin (3H-DADL) to delta sites and of [3H]-bremazocine to kappa sites were not significantly affected in any region. In contrast, after administration of a higher dose of naloxone (3.0 mg/kg/hr), the binding to mu, delta and kappa sites was increased in many brain areas, suggesting that up-regulation is observed only when a sufficient proportion of the receptors in vivo are occupied by the antagonist. However, a different regional pattern of up-regulation was seen for each class of opiate binding site. The greatest increases in kappa binding in the brain were seen in the periaqueductal gray and the hippocampal molecular and pyramidal cell layers. The substantia nigra showed up-regulation of kappa but not of mu sites. Differences in the pattern of mu and kappa binding site up-regulation were also noted in the spinal cord. This regionally specific modulation of opiate binding sites suggests that, for each receptor type, the level of tonic activation varies between individual brain areas. In addition, the data demonstrate that all three types of opiate receptor can undergo up-regulation "in vivo."
采用定量体外放射自显影技术,对慢性输注纳洛酮后观察到的对μ或κ阿片受体激动剂超敏反应的神经化学基础进行了研究(前文已报道)。低剂量纳洛酮(0.5毫克/千克/小时)慢性给药(7天)后,许多脑区中[3H]-D-丙氨酸2-甲基苯丙氨酸4-甘氨酰胺脑啡肽(3H-DAGO)与μ阿片受体位点的结合增加。海马分子层和透明层的增加最为显著。[3H]-D-丙氨酸2-D-亮氨酸5脑啡肽(3H-DADL)与δ受体位点的结合以及[3H]-布马佐辛与κ受体位点的结合在任何区域均未受到显著影响。相比之下,给予较高剂量的纳洛酮(3.0毫克/千克/小时)后,许多脑区中与μ、δ和κ受体位点的结合均增加,这表明只有当体内足够比例的受体被拮抗剂占据时才会出现上调。然而,每类阿片受体结合位点的上调区域模式不同。脑中κ受体结合增加最为显著的区域是导水管周围灰质以及海马分子层和锥体细胞层。黑质中κ受体出现上调,但μ受体位点未上调。在脊髓中也注意到μ和κ受体结合位点上调模式的差异。阿片受体结合位点的这种区域特异性调节表明,对于每种受体类型,各个脑区的紧张性激活水平各不相同。此外,数据表明所有三种类型的阿片受体均可在“体内”发生上调。